MX2020001305A - Metodos para tratar la esofagitis eosinofilica activa. - Google Patents
Metodos para tratar la esofagitis eosinofilica activa.Info
- Publication number
- MX2020001305A MX2020001305A MX2020001305A MX2020001305A MX2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A MX 2020001305 A MX2020001305 A MX 2020001305A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- eosinophilic esophagitis
- present
- treating active
- active eosinophilic
- Prior art date
Links
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 title abstract 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 title abstract 2
- 102000003816 Interleukin-13 Human genes 0.000 abstract 1
- 108090000176 Interleukin-13 Proteins 0.000 abstract 1
- 102000004388 Interleukin-4 Human genes 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 102000002171 Interleukin-4/interleukin-13 Human genes 0.000 abstract 1
- 108050009538 Interleukin-4/interleukin-13 Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541242P | 2017-08-04 | 2017-08-04 | |
| US201762561593P | 2017-09-21 | 2017-09-21 | |
| EP18305252 | 2018-03-08 | ||
| PCT/US2018/045195 WO2019028367A1 (en) | 2017-08-04 | 2018-08-03 | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001305A true MX2020001305A (es) | 2020-03-09 |
Family
ID=63113646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001305A MX2020001305A (es) | 2017-08-04 | 2018-08-03 | Metodos para tratar la esofagitis eosinofilica activa. |
| MX2024012777A MX2024012777A (es) | 2017-08-04 | 2020-01-31 | Uso de un inhibidor de la via de interleucina-4/interleucina-13 (il-4/il-13) para tratar la esofagitis eosinofilica activa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012777A MX2024012777A (es) | 2017-08-04 | 2020-01-31 | Uso de un inhibidor de la via de interleucina-4/interleucina-13 (il-4/il-13) para tratar la esofagitis eosinofilica activa |
Country Status (9)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3174431A1 (en) * | 2020-05-22 | 2021-11-25 | Jennifer D. Hamilton | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| AU2023259287A1 (en) * | 2022-04-29 | 2024-12-12 | Akeso Biopharma, Inc | Anti-human il-4ra antibody and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682781B (zh) * | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR20160068802A (ko) * | 2013-10-23 | 2016-06-15 | 제넨테크, 인크. | 호산구성 장애를 진단 및 치료하는 방법 |
| KR20170123315A (ko) * | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
-
2018
- 2018-08-02 IL IL315556A patent/IL315556A/en unknown
- 2018-08-03 MX MX2020001305A patent/MX2020001305A/es unknown
- 2018-08-03 CA CA3071528A patent/CA3071528A1/en active Pending
- 2018-08-03 AU AU2018311981A patent/AU2018311981B2/en active Active
- 2018-08-03 MA MA049744A patent/MA49744A/fr unknown
- 2018-08-03 CN CN201880050334.6A patent/CN111032084A/zh active Pending
- 2018-08-03 JP JP2020505844A patent/JP7417515B2/ja active Active
- 2018-08-03 IL IL272245A patent/IL272245B2/en unknown
- 2018-08-03 EP EP18750578.9A patent/EP3661551A1/en active Pending
- 2018-08-03 KR KR1020207006346A patent/KR102719720B1/ko active Active
- 2018-08-03 KR KR1020247034392A patent/KR20240152980A/ko active Pending
-
2020
- 2020-01-31 MX MX2024012777A patent/MX2024012777A/es unknown
-
2023
- 2023-11-13 JP JP2023192683A patent/JP2024016237A/ja active Pending
-
2025
- 2025-02-12 AU AU2025200955A patent/AU2025200955A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024016237A (ja) | 2024-02-06 |
| CN111032084A (zh) | 2020-04-17 |
| MA49744A (fr) | 2020-06-10 |
| AU2018311981A1 (en) | 2020-02-20 |
| CA3071528A1 (en) | 2019-02-07 |
| AU2018311981B2 (en) | 2024-11-14 |
| KR20240152980A (ko) | 2024-10-22 |
| IL272245B2 (en) | 2025-02-01 |
| AU2025200955A1 (en) | 2025-03-06 |
| RU2020109331A3 (enrdf_load_stackoverflow) | 2021-12-28 |
| IL272245A (en) | 2020-03-31 |
| JP2020529434A (ja) | 2020-10-08 |
| EP3661551A1 (en) | 2020-06-10 |
| RU2020109331A (ru) | 2021-09-06 |
| IL272245B1 (en) | 2024-10-01 |
| MX2024012777A (es) | 2024-11-08 |
| KR20200035442A (ko) | 2020-04-03 |
| IL315556A (en) | 2024-11-01 |
| JP7417515B2 (ja) | 2024-01-18 |
| KR102719720B1 (ko) | 2024-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122909T1 (el) | Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r | |
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| MY208549A (en) | Parp1 inhibitors | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| NZ777396A (en) | Therapeutic compositions, combinations, and methods of use | |
| PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
| MY195443A (en) | Tissue Factor Pathway Inhibitor Antibodies and uses Thereof | |
| PH12014501106B1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
| EP4434344A3 (en) | Compositions comprising recombinant bacillus cells and an insecticide | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2015009651A (es) | Composiciones y metodos para el tratamiento de plagas. | |
| MX393693B (es) | Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofílica | |
| MX2018003713A (es) | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). | |
| MX2016011537A (es) | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. | |
| AU2016335217A8 (en) | Antigen receptors and uses thereof | |
| EA201890728A3 (ru) | Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами | |
| MX2022004373A (es) | Celulas madre modificadas y metodos de uso de las mismas. | |
| MX2021015210A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MX2020013269A (es) | Inhibidores de la vía de respuesta al estrés integrada. | |
| UA122488C2 (uk) | Композиція для підвищення ефективності приживання гемопоетичних стовбурових клітин після трансплантації | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| TN2014000086A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| MX2020001305A (es) | Metodos para tratar la esofagitis eosinofilica activa. | |
| MX2024014054A (es) | Inhibidores de sintasa de oxido neuronal para inmunoterapia | |
| MX2016009600A (es) | Agentes para utilizarse en el tratamiento de la inflamacion de retina. |